PLRX (Pliant Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PLRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | Flavia Borellini | Director | A | — | — |
| 2026-07-13 | Robert Iannone | Director | A | — | — |
| 2026-06-12 | Steve E. Krognes | Director | A | — | — |
| 2026-06-12 | Hoyoung Huh | Director | A | — | — |
| 2026-06-12 | Darren S Cline | Director | A | — | — |
| 2026-06-12 | GAYLE A CROWELL | Director | A | — | — |
| 2026-06-12 | John T Curnutte | Director | A | — | — |
| 2026-06-12 | Thomas A MCCOURT | Director | A | — | — |
| 2026-04-17 | Keith Lamont Cummings | Chief Financial Officer | MIXED | — | — |
| 2026-04-17 | Bernard Coulie | President and CEO | MIXED | — | — |
| 2026-04-17 | Lily Cheung | Chief Human Resource Officer | MIXED | — | — |
| 2026-04-17 | Minnie Kuo | Chief Operating Officer | MIXED | — | — |
| 2026-01-26 | Minnie Kuo | Chief Operating Officer | A | — | — |
| 2026-01-26 | Keith Lamont Cummings | Chief Financial Officer | A | — | — |
| 2026-01-26 | Bernard Coulie | President and CEO | A | — | — |
| 2026-01-26 | Lily Cheung | Chief Human Resource Officer | A | — | — |
| 2026-01-22 | Keith Lamont Cummings | Chief Financial Officer | Sell | — | — |
| 2026-01-22 | Minnie Kuo | Chief Operating Officer | Sell | — | — |
| 2026-01-22 | Lily Cheung | Chief Human Resource Officer | Sell | — | — |
| 2026-01-22 | Bernard Coulie | President and CEO | Sell | — | — |
| 2025-06-09 | Thomas A MCCOURT | Director | A | — | — |
| 2025-06-09 | Katharine Knobil | Director | A | — | — |
| 2025-06-09 | Suzanne Louise Bruhn | Director | A | — | — |
| 2025-06-09 | John T Curnutte | Director | A | — | — |
| 2025-06-09 | DAVID E I PYOTT | Director | A | — | — |
| 2025-06-09 | Hoyoung Huh | Director | A | — | — |
| 2025-06-09 | Steve E. Krognes | Director | A | — | — |
| 2025-06-09 | Darren S Cline | Director | A | — | — |
| 2025-06-09 | GAYLE A CROWELL | Director | A | — | — |
| 2025-01-27 | Lily Cheung | Chief Human Resource Officer | A | — | — |
| 2025-01-27 | Eric Lefebvre | Chief Medical Officer | A | — | — |
| 2025-01-27 | Hans Hull | Chief Business Officer | A | — | — |
| 2025-01-27 | Bernard Coulie | President and CEO | A | — | — |
| 2025-01-27 | Keith Lamont Cummings | Chief Financial Officer | A | — | — |
| 2025-01-27 | Mike Ouimette | General Counsel & Corp. Sec'y | A | — | — |
| 2025-01-22 | Lily Cheung | Chief Human Resource Officer | Sell | — | — |
| 2025-01-22 | Eric Lefebvre | Chief Medical Officer | Sell | — | — |
| 2025-01-22 | Keith Lamont Cummings | Chief Financial Officer | Sell | — | — |
| 2025-01-22 | Bernard Coulie | President and CEO | Sell | — | — |
| 2025-01-22 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | — | — |
| 2025-01-22 | Hans Hull | Chief Business Officer | Sell | — | — |
| 2024-07-12 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | — | — |
| 2024-07-12 | Keith Lamont Cummings | Chief Financial Officer | Sell | — | — |
| 2024-07-12 | Eric Lefebvre | Chief Medical Officer | Sell | — | — |
| 2024-07-12 | Bernard Coulie | President and CEO | Sell | — | — |
| 2024-07-12 | Hans Hull | Chief Business Officer | Sell | — | — |
| 2024-07-11 | Mike Ouimette | General Counsel & Corp. Sec'y | A | — | — |
| 2024-07-11 | Hans Hull | Chief Business Officer | A | — | — |
| 2024-07-11 | Bernard Coulie | President and CEO | A | — | — |
| 2024-07-11 | Eric Lefebvre | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,972,027 | — |
| — | 10%+ Owner | 2,362,371 | — |
| — | 10%+ Owner | 1,910,657 | — |
| — | President and CEO | 914,918 | — |
| — | Chief Financial Officer | 297,214 | — |
| — | Chief Business Officer | 255,529 | — |
| — | Chief Medical Officer | 240,224 | — |
| — | Director | 239,619 | — |
| — | General Counsel & Corp. Sec'y | 105,544 | — |
| — | Chief Human Resource Officer | 44,847 | — |
| — | Chief Operating Officer | 37,806 | — |
| — | Chief Human Resource Officer | 24,799 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PLRX quote page; the site-wide leaderboard is on the insider transactions hub.